Verge Genomics is a clinical-stage biotechnology company developing drugs using CONVERGE, an all-in-human artificial-intelligence-powered platform for drug discovery. Rather than relying primarily on animal models or cell cultures, the company begins its research directly in human tissue, building large proprietary multi-omics databases to inform candidate selection.
The platform integrates machine learning with internal biology and chemistry capabilities to discover and develop drug candidates for neurological diseases. The company's first clinical candidate, VRG50635, entered clinical testing for amyotrophic lateral sclerosis. Verge Genomics maintains multiple clinical-stage programs and collaborates with industry partners to advance its pipeline.
The company positions itself around a core hypothesis: starting research in human biology rather than traditional preclinical models improves the probability of clinical success and translational efficacy. Its approach combines large-scale human genomic data with computational methods to identify disease mechanisms and therapeutic targets in conditions where treatment options remain limited.